Analyst Price Targets — SRRK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 21, 2026 3:35 pm | — | Wedbush | $64.00 | $55.97 | TheFly | Scholar Rock price target raised to $64 from $58 at Wedbush |
| August 7, 2026 11:57 am | — | BMO Capital | $76.00 | $52.18 | TheFly | Scholar Rock price target raised to $76 from $70 at BMO Capital |
| May 8, 2026 10:35 am | — | Barclays | $55.00 | $46.45 | TheFly | Scholar Rock price target raised to $55 from $53 at Barclays |
| May 8, 2026 10:22 am | — | H.C. Wainwright | $65.00 | $46.45 | TheFly | Scholar Rock price target raised to $65 from $58 at H.C. Wainwright |
| April 20, 2026 8:21 pm | — | Canaccord Genuity | $62.00 | $47.80 | TheFly | Scholar Rock initiated with a Buy at Canaccord |
| March 4, 2026 12:55 pm | Allison Bratzel | Piper Sandler | $58.00 | $44.85 | StreetInsider | 'We are incrementally positive on Scholar Rock (SRRK) Shares'; PT Raised at Piper Sandler |
| March 3, 2026 9:01 pm | Etzer Darout | Barclays | $53.00 | $44.31 | StreetInsider | Scholar Rock (SRRK) PT Raised to $53 at Barclays |
| March 3, 2026 6:54 pm | Srikripa Devarakonda | Truist Financial | $55.00 | $44.31 | StreetInsider | Scholar Rock (SRRK) PT Raised to $55 at Truist Securities |
| January 26, 2026 11:16 am | Andres Maldonado | H.C. Wainwright | $58.00 | $44.29 | TheFly | Scholar Rock price target raised to $58 from $44 at H.C. Wainwright |
| January 7, 2026 6:02 am | Michael Yee | UBS | $60.00 | $41.31 | StreetInsider | UBS Starts Scholar Rock (SRRK) at Buy |
Latest News for SRRK
Beaconlight Capital LLC purchased a new stake in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 87,893 shares of the company's stock, valued at approximately $4,834,000. Scholar Rock makes up about 1.7%
BlackRock Inc. acquired a new position in shares of Scholar Rock Holding Corporation (NASDAQ: SRRK) in the undefined quarter, according to its most recent filing with the SEC. The fund acquired 9,494,084 shares of the company's stock, valued at approximately $522,175,000. BlackRock Inc. owned approximately 7.92% of Scholar Rock at the end of
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced it has successfully removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from its apitegromab Biologics…
Scholar Rock NASDAQ: SRRK CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, or SMA, following a resubmitted biologics license application supported by an alternate fill-finish manufacturing facility.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to purchase an aggregate of 14,889 shares of common stock and inducement restricted stock units, covering an aggregate of 37,058 shares of its…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SRRK.
U.S. House Trading
No House trades found for SRRK.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.